10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
10x Genomics, Inc.NASDAQ: TXG
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue declines year over year
Q3 FY2026 cost of revenue of $37.74M fell 22.5% year over year, behind the -13.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 2.1% from the prior quarter. Over 3 fiscal years it compounded at +18.2% a year.
Context
- Cost of revenue amounted to 30.9% of revenue in FY2025, down 1.2 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -22.5% toward the trailing-twelve-month pace of -13.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 198.94M USD
- Year-over-year change
- +1.3%
- 4-year CAGR
- +28.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 198.94M | +1.3% |
| FY2024 | 2024-12-31 | 196.3M | -6.3% |
| FY2023 | 2023-12-31 | 209.41M | +74.0% |
| FY2022 | 2022-12-31 | 120.39M | +62.5% |
| FY2021 | 2021-12-31 | 74.09M | — |
Cost of Revenue vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's LTM Sep 2026 cost of revenue of $173.93M is the 8th highest of the 9 companies compared; the peer median is $1.02B.
- Its year-over-year change of -13.0% is the 8th highest of 9, against a peer median of +6.1%.
- Cost of revenue amounts to 28.1% of revenue for TXG, versus a peer median of 46.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $3.41B | +6.8% | +1.9% | 46.3% | |
| LTM Jun 2026 | $1.49B | +6.0% | -3.6% | 33.2% | |
| LTM Jul 2026 | $1.39B | +8.5% | -4.8% | 47.9% | |
| LTM Jun 2026 | $1.25B | +3.4% | +0.1% | 48.1% | |
| LTM Jun 2026 | $801.85M | +6.1% | +1.8% | 38.2% | |
| LTM Sep 2026 | $420.61M | -0.2% | +4.3% | 34.2% | |
| LTM Sep 2026 | $218.63M | +17.8% | +12.1% | 47.6% | |
| LTM Sep 2026 | $173.93M | -13.0% | +18.2% | 28.1% | |
| LTM Mar 2026 | $44.6M | -34.2% | -11.1% | 51.7% | |
| Peer median (excluding TXG) | $1.02B | +6.1% | +1.0% | 46.9% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 490.49M | 516.41M | 618.73M | 610.79M | 642.82M |
| Cost of Revenue | 74.09M | 120.39M | 209.41M | 196.3M | 198.94M |
| Gross Profit | 416.4M | 396.02M | 409.31M | 414.48M | 443.88M |
| Gross Margin | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Research & Development | 211.75M | 265.67M | 270.33M | 264.7M | 238.63M |
| Selling, General & Admin | 257.56M | 298.3M | 343.33M | 344.34M | 316.13M |
| Operating Expenses | 469.31M | 563.97M | 674.64M | 609.04M | 554.77M |
| Depreciation & Amortization | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| EBITDA | (24.6M) | (128.49M) | (205.11M) | (133.99M) | 3.91M |
| EBITDA Margin | -5.0% | -24.9% | -33.2% | -21.9% | 0.6% |
| Operating Income | (52.91M) | (167.94M) | (265.33M) | (194.56M) | (110.89M) |
| Operating Margin | -10.8% | -32.5% | -42.9% | -31.9% | -17.2% |
| Interest Income | 206K | 6.65M | 16.91M | 18.45M | 20.05M |
| Interest Expense | 866K | 476K | 33K | 4K | 0 |
| Other Income / Expenses | (802K) | 5.97M | 16.57M | 16.86M | 70.98M |
| Income Before Tax | (53.72M) | (161.97M) | (248.76M) | (177.7M) | (39.91M) |
| Pre-Tax Margin | -11.0% | -31.4% | -40.2% | -29.1% | -6.2% |
| Income Tax Expense | 4.51M | 4.03M | 6.34M | 4.93M | 3.64M |
| Net Income | (58.22M) | (166M) | (255.1M) | (182.63M) | (43.54M) |
| Net Margin | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
| EPS (Basic) | (0.53) | (1.46) | (2.18) | (1.52) | (0.35) |
| EPS (Diluted) | (0.53) | (1.46) | (2.18) | (1.52) | (0.35) |
| Weighted Avg Shares | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
| Weighted Avg Shares (Diluted) | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.